Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Surgery, Fu Jen Catholic University Hospital, Fu Jen Catholic University, New Taipei City, Taiwan; School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Surgery & Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
Eur J Surg Oncol. 2020 May;46(5):811-817. doi: 10.1016/j.ejso.2019.12.006. Epub 2019 Dec 10.
Irreversible electroporation (IRE) is a modality that utilizes high electric voltage to cause cell apoptosis. IRE has been used to treat locally advanced pancreatic cancer (LAPC). However, studies of IRE via surgical approaches for LAPC are limited. This study aims to analyse the outcomes and related prognostic factors of IRE for Asian patients with LAPC.
From 2012 to 2017, this prospective trial for using IRE through surgical approaches for LAPC was conducted in 11 medical centres in Asia. All related and treatment outcomes were analysed from a prospective database.
Seventy-four patients were enrolled. Thirty complications occurred in thirteen (17.6%) patients without mortality. The electrode placement direction (anteroposterior vs. craniocaudal, HR = 14.2, p < 0.01) and gastrointestinal invasion (HR = 15.7, p < 0.01) were significant factors for complications. The progression-free survival (PFS) rate in one year, three years, and five years were 69.1%, 48.7%, and 28.8%, and the overall survival (OS) rate in one year, three years, and five years were 97.2%, 53%, and 31.2%. In univariate analysis, the chemotherapy regimen, local tumour recurrence, axial tumour length, tumour volume, and serum carbohydrate antigen 19-9 levels were all significantly associated with PFS and OS. In multivariate analysis, the chemotherapy regimen was the only significant factor associated with PFS and OS. TS-1 (Tegafur, gimeracil, and oteracil) group has superior survival outcome than gemcitabine group.
This study showed that combined induction chemotherapy and surgical IRE for LAPC is safe. For well-selected patients, IRE can achieve encouraging survival outcomes.
不可逆电穿孔(IRE)是一种利用高电压导致细胞凋亡的方法。IRE 已被用于治疗局部晚期胰腺癌(LAPC)。然而,通过手术方法治疗 LAPC 的 IRE 研究有限。本研究旨在分析 IRE 治疗亚洲 LAPC 患者的结果和相关预后因素。
2012 年至 2017 年,这项通过手术方法治疗 LAPC 的 IRE 的前瞻性研究在亚洲的 11 家医疗中心进行。所有相关的治疗结果均从前瞻性数据库中进行分析。
共纳入 74 例患者。13 例患者发生 30 例并发症,无死亡病例。电极放置方向(前后 vs. 头足)和胃肠道侵犯(HR=14.2,p<0.01)是并发症的显著因素。一年、三年和五年的无进展生存率(PFS)分别为 69.1%、48.7%和 28.8%,一年、三年和五年的总生存率(OS)分别为 97.2%、53%和 31.2%。单因素分析显示,化疗方案、局部肿瘤复发、肿瘤轴向长度、肿瘤体积和血清碳水化合物抗原 19-9 水平与 PFS 和 OS 均显著相关。多因素分析显示,化疗方案是与 PFS 和 OS 相关的唯一显著因素。替吉奥(Tegafur、gimeracil 和oteracil)组的生存结果优于吉西他滨组。
本研究表明,联合诱导化疗和手术 IRE 治疗 LAPC 是安全的。对于选择合适的患者,IRE 可以实现令人鼓舞的生存结果。